FIELD: imaging and endoradiotherapy of diseases.
SUBSTANCE: invention is related to diseases in which prostate specific membrane antigen (PSMA) is involved. Compounds that bind or inhibit PSMA and, in addition, have at least one fragment capable of labelling with radioactive labels, are presented. Medical applications of such compounds are also presented.
EFFECT: imaging and endoradiotherapy inventions are proposed.
13 cl, 6 dwg, 10 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW PSA-BINDING AGENTS AND THEIR USE | 2018 |
|
RU2787105C2 |
| NOVEL TUMOR ANTIGEN BINDING AGENTS AND USE THEREOF | 2019 |
|
RU2831681C2 |
| INHIBITORS OF VIIA FACTOR | 1999 |
|
RU2223967C2 |
| RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS AND THEIR USE | 2018 |
|
RU2804297C2 |
| PSMA-TARGET COMPOUND AND ITS COMPLEX WITH RADIONUCLIDES FOR THERANOSTICS OF TUMOR EXPRESSING PSMA | 2022 |
|
RU2803734C1 |
| LIGANDS FOR MELANOCORTIN RECEPTORS | 2001 |
|
RU2246501C2 |
| COMPOUND HAVING TARGETED EFFECT ON PROSTATE-SPECIFIC MEMBRANE ANTIGEN, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2022 |
|
RU2832300C2 |
| SYNTHETIC PEPTIDES REDUCING OR ELIMINATING BAGGY LOWER EYELIDS, AND APPLICATION THEREOF IN COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS | 2005 |
|
RU2387666C2 |
| SOMATOSTATIN ANTAGONISTS | 2002 |
|
RU2263678C2 |
| OXYTOCIN ANALOGUES | 2009 |
|
RU2496788C2 |
